跳至主要内容
临床试验/NCT00989105
NCT00989105终止1 期

A Cancer Research UK Phase I Trial of 99mTc Demobesin-4 (a Diagnostic Radiopharmaceutical) Given Once Via Bolus Intravenous Injection for Imaging of Prostate Cancer

Cancer Research UK2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2009年6月最近更新:
适应症

试验速览

阶段
1 期
状态
终止
入组人数
8
试验地点
2
主要终点
Biodistribution of radioactivity of 99mTc DB4 by gamma-camera imaging

研究概览

简要总结

RATIONALE: Diagnostic procedures, such as technetium Tc 99m demobesin-4 followed by single-photon emission computer tomography, CT scan, and MRI, may help find prostate cancer and learn the extent of disease.

PURPOSE: This phase I trial is studying the side effects of technetium Tc 99m demobesin-4 and to see how well it works for imaging procedures in patients with prostate cancer.

详细描述

OBJECTIVES:

Primary

  • To assess the safety of technetium Tc 99m (^99mTc) demobesin-4 (DB4) in patients with prostate cancer.
  • To assess the biodistribution of ^99mTc DB4 in these patients.
  • To assess the pharmacokinetics of ^99mTc DB4 in these patients.

Secondary

  • To assess the performance of ^99mTc DB4 in detecting metastatic spread of prostate cancer in these patients.

研究设计

研究类型
Interventional
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Biodistribution of radioactivity of 99mTc DB4 by gamma-camera imaging

Pharmacokinetics of 99mTc DB4 in blood and urine and assessment of decline over 6 hours

Causality of each adverse events as assessed by NCI CTCAE v. 3.0

次要结局

  • Performance of 99mTc DB4 gamma-camera imaging compared with conventional imaging (CT scan and/or MRI)
  • Levels of expression in gastrin-releasing peptide in prostate tumor samples and lymph node specimens

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验